Clinical bottom line
Novel mRNA vaccines beyond COVID-19 represent a promising platform for infectious diseases and oncology, but their potential to trigger allergic reactions remains an evolving clinical concern. Current evidence, largely extrapolated from extensive COVID-19 mRNA vaccine experience, indicates that immediate hypersensitivity reactions including anaphylaxis are rare but can occur. Most reactions are manageable with established allergy protocols, and risk stratification prior to vaccination is feasible. However, data specific to non-COVID-19 mRNA vaccines are limited, warranting cautious extrapolation. Clinicians should remain vigilant for allergic events, apply validated diagnostic and management strategies, and contribute to ongoing pharmacovigilance as these vaccines enter broader clinical use.
What the evidence shows
The COVID-19 pandemic accelerated the deployment of mRNA vaccines, providing the largest dataset on allergic reactions to this novel platform. Early reports documented acute allergic reactions and anaphylaxis occurring at rates estimated between 2 and 11 cases per million doses administered (Kelso et al., 2021; Maki et al., 2021). The primary suspected allergens include polyethylene glycol (PEG) and related excipients, which are also components of other mRNA formulations (Kelso et al., 2021).
Specialist-confirmed allergic reactions at mass vaccination sites were rare, and most patients tolerated subsequent doses with appropriate precautions (Myles et al., 2021). Diagnostic algorithms incorporating skin testing and graded vaccine challenges have been proposed and validated in COVID-19 vaccine recipients, facilitating safe administration in patients with prior reactions (Maki et al., 2021).
Safety data in special populations, including pregnant individuals and those with prior COVID-19 infection, have shown no increased risk of allergic events, supporting broad vaccine use (Reactions Weekly, 2022). Importantly, no association has been found between mRNA vaccines and menstrual irregularities, which may be relevant for counseling (Reactions Weekly, 2023).
While these findings provide a framework, direct evidence on allergic reactions to novel mRNA vaccines beyond COVID-19 remains sparse. The immunogenic components and excipient profiles of future mRNA vaccines may differ, potentially altering allergenic risk profiles.
Caveats and uncertainty
The extrapolation of COVID-19 mRNA vaccine allergy data to other mRNA vaccines is limited by differences in antigen targets, lipid nanoparticle formulations, and excipient composition. The incidence and severity of allergic reactions may vary accordingly. Post-marketing surveillance and real-world data collection will be critical to characterize these risks.
Current diagnostic and management guidelines are based predominantly on COVID-19 vaccine experience and may require adaptation for other mRNA vaccines. The role of pre-vaccination allergy testing remains debated, with some evidence suggesting limited predictive value outside of known PEG allergy (Maki et al., 2021).
Additionally, the mechanisms underlying mRNA vaccine-related allergic reactions are incompletely understood, with hypotheses including IgE-mediated and non-IgE-mediated pathways. This uncertainty complicates risk stratification and management.
How this may change practice
Clinicians should apply lessons learned from COVID-19 mRNA vaccine allergy management when evaluating patients receiving novel mRNA vaccines. This includes:
- Vigilant monitoring for immediate hypersensitivity reactions during and after vaccination.
- Utilizing established diagnostic protocols, including detailed history, skin testing, and graded challenges where indicated.
- Educating patients on the rarity and treatability of allergic reactions to support vaccine confidence.
- Reporting suspected allergic events to pharmacovigilance systems to inform evolving safety profiles.
- Collaborating with allergy specialists for complex cases or patients with prior severe reactions.
As novel mRNA vaccines become more prevalent, allergy clinicians will play a pivotal role in ensuring safe administration and optimizing patient outcomes through evidence-based approaches.